Oregovomab

From WikiMD's WELLNESSPEDIA

(Redirected from OvaRex)

Oregovomab is a monoclonal antibody used in the treatment of ovarian cancer. It targets the antigen CA-125, which is often elevated in ovarian cancer patients. Oregovomab is designed to stimulate the patient's immune system to recognize and attack cancer cells expressing CA-125.

Mechanism of Action[edit]

Oregovomab binds to the CA-125 antigen, which is present on the surface of ovarian cancer cells. This binding event is thought to activate the immune system, particularly T-cells, which then learn to recognize and kill cells expressing CA-125. This approach is part of a broader category of cancer therapy known as immunotherapy, which aims to boost the body's own immune system to fight cancer.

Clinical Trials[edit]

Oregovomab has been evaluated in several clinical trials. Early phase trials focused on assessing its safety and optimal dosing strategies. Subsequent trials have evaluated its efficacy, often comparing it with standard chemotherapy treatments or in combination with other therapeutic agents. The results of these trials have been mixed, with some showing promise in extending survival or delaying disease progression, while others have not demonstrated significant benefits.

Usage[edit]

The use of oregovomab is typically considered in cases of advanced ovarian cancer where traditional therapies have failed or as part of a clinical trial setting. Its administration involves intravenous infusions, and the treatment regimen can vary depending on the specific clinical trial or treatment protocol.

Side Effects[edit]

As with many cancer treatments, oregovomab can cause side effects. These may include flu-like symptoms such as fever, chills, and fatigue, which are common to treatments that stimulate the immune system. More severe immune-related adverse effects can also occur, although they are less common.

Current Status[edit]

As of the last update, oregovomab is not widely used outside of clinical trials. Research is ongoing to better understand its potential role in ovarian cancer treatment, including its use in combination with other therapies.

See Also[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Oregovomab&oldid=6525458"